EXCLUSIVE: New Alzheimer’s Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says

InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons.

During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the company’s research and its potential implications for Alzheimer’s treatment.

Neuroprotective Effects and Beyond

InMed’s research focuses on a specific cannabinoid compound that has demonstrated promising neuroprotective effects. This compound not only helps prevent neuron death but also assists in reducing disease-related neuron degeneration.

The team at InMed has observed that the compound aids in the regrowth of neuron connections, which are crucial for cognitive functions.

In addition to its neuroprotective capabilities, the compound has shown effectiveness in decreasing neuroinflammation, a critical factor in the pathology of dementia, says Adams.

“We …

Full story available on Benzinga.com